Noritomo Shimada

Chiba-Nishi General Hospital — Japan

Medicine · Health Sciences

35h-index3.9kcitations183works4.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(88), Liver Disease Diagnosis and Treatment(84), Hepatitis C virus research(82), Hepatitis B Virus Studies(42), HIV/AIDS drug development and treatment(23)

Publications178 total

Evaluating the Implementation of Mother-to-Child Transmission Prevention Measures and Interdepartmental Collaboration for HBV-Positive Pregnant Women and Their Newborns
Kanzo·2025Open Access
ENDOSCOPIC MANAGEMENT OF DUODENAL VARIX: A CASE REPORT
Gastrointestinal Endoscopy·2025
BOWEL PREPARATION ON THE DIAGNOSTIC YIELD OF BLEEDING SOURCE IN COLONIC DIVERTICULAR BLEEDING: A COMPARATIVE STUDY OF COLONOSCOPY WITH AND WITHOUT BOWEL PREPARATION
Gastrointestinal Endoscopy·2025
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
Scientific Reports·2025· 1 citedOpen Access
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study
Oncology·2024· 4 cited
Prognostic Efficacy of the Albumin Grade in Patients with Hepatocellular Carcinoma.
PubMed·2024Open Access
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
Targeted Oncology·2024· 7 citedOpen Access
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
Liver Cancer·2024· 19 citedOpen Access
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Cancer Reports·2024· 10 citedOpen Access
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
Liver International·2024· 4 cited
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma
Journal of Gastroenterology and Hepatology·2024· 2 citedOpen Access
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma
Targeted Oncology·2024· 2 citedOpen Access
<scp>α‐FAtE</scp>: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
International Journal of Cancer·2023· 10 citedOpen Access
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study
Hepatology Research·2023· 14 cited
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach
Cancer Medicine·2023· 8 citedOpen Access
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
2023Open Access
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
2023· 2 citedOpen Access
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma
Liver International·2023· 12 citedOpen Access
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
Cancers·2023· 12 citedOpen Access
Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
Cancer Medicine·2023· 6 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Koichi Takaguchi(43), Takashi Kumada(41), Hidenori Toyoda(41), Atsushi Hiraoka(40), Toru Ishikawa(40), Kunihiko Tsuji(39), Masanori Atsukawa(37), Toshifumi Tada(36), Ei Itobayashi(32), Yoichi Hiasa(32), Akemi Tsutsui(31), Norio Itokawa(31), Kazuya Kariyama(30), Hironori Ochi(30), Kazuto Tajiri(30), Masashi Hirooka(30), Kazuhiro Nouso(30), Michitaka Imai(28), Yohei Koizumi(26), Shinya Fukunishi(25)